- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.11. | Lyell acquires worldwide rights from ICT to CAR T-cell therapy | ||
| 11.11. | Novartis opens California site for RLT manufacturing | ||
| 10.11. | Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal | ||
| 10.11. | CPHI 2025: directing AI-driven innovation to harness Europe's data edge | ||
| 10.11. | Harbour BioMed and Evinova collaborate on AI biologics | ||
| 10.11. | Pfizer clinches $10bn Metsera deal as Novo Nordisk retreats | ||
| 10.11. | Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer | ||
| 10.11. | SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases | ||
| 07.11. | Rhythm forced to wait for Imcivree expansion as FDA delays decision | ||
| 07.11. | J&J's Darzalex gains first FDA approval in smouldering multiple myeloma | ||
| 07.11. | Trump hits long-term pledge as US prices of weight loss drugs slashed | ||
| 07.11. | Abzena and Mabqi partner for drug development solution | ||
| 07.11. | Alvotech and Advanz announce MHRA marketing authorisations for Gobivaz | ||
| 06.11. | J&J's Caplyta wins MDD approval to extend revenue horizon | ||
| 06.11. | Former blockbuster Linzess grows label with paediatric IBS-C approval | ||
| 06.11. | Novo Nordisk's oral Wegovy reduces cardiovascular risk factors in obesity | ||
| 06.11. | Cencora to invest $1bn in US pharma distribution network | ||
| 06.11. | Leukogene Therapeutics gains FDA ODD status for M2T-CD33 | ||
| 05.11. | Novo Nordisk latest outlook trim shows "quick momentum loss" | ||
| 05.11. | Agentic, deeply embedded AI constitutes the "next wave" of tech | ||
| 05.11. | Avant and SGAustria form JV to develop diabetes therapy | ||
| 05.11. | Novo Nordisk and Pfizer's bidding war for Metsera escalates despite legal threats | ||
| 05.11. | MSD secures $700m for broad-cancer ADC asset | ||
| 05.11. | AmacaThera and Pacira sign agreement for AMT-143 | ||
| 05.11. | Boehringer and CDR-Life announce licensing deal for autoimmune disease therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .